secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aardvark Therapeutics, Inc. (AARD)
CIK:        0001774857
Form:       8-K
Filed at:   2025-08-12T23:59:59+00:00
Accession:  0000950170-25-107320
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aardvark reports ARD-201 preclinical data: 19% weight loss in mice; plans two Phase 2 trials
--------------------------------------------------------------------------------

- ARD-201 monotherapy achieved ~19% body weight reduction in DIO mice after 30 days.
- ARD-201 attenuated weight regain after tirzepatide withdrawal; combo with low-dose tirzepatide outperformed high-dose tirzepatide alone.
- Phase 2 POWER trial (2H 2025) targets weight regain prevention in patients discontinuing GLP-1RA therapy.
- Phase 2 STRENGTH trial (1H 2026) to test monotherapy and combination with GLP-1RA, replacing prior EMPOWER trial.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1774857/000095017025107320/0000950170-25-107320-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1774857/000095017025107320/ck0001774857-20250812.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-107320

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer